SCHEMBL469047

SCHEMBL469047

N[C@@H]1CCCc2ccccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 4/20 0.58
HTR2A P28223 2/20 0.45
RET P07949 1/20 0.45
TSHR P16473 1/20 0.44
ADRA2A P08913 2/20 0.44
ADRA1A P35348 2/20 0.44
LMNA P02545 1/20 0.44
ADRA1D P25100 1/20 0.44
ADRA1B P35368 1/20 0.44
HTR1A P08908 1/20 0.44
OPRM1 P35372 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29415502 1.00 IDO1 (0.58) IDO1HTR2ARETTSHRADRA2A
SCHEMBL40422 1.00 IDO1 (0.58) IDO1HTR2ARETTSHRADRA2A
SCHEMBL30837489 1.00 IDO1 (0.58) IDO1HTR2ARETTSHRADRA2A
SCHEMBL14543304 1.00 IDO1 (0.58) IDO1HTR2ARETTSHRADRA2A
SCHEMBL10774751 1.00 IDO1 (0.58) IDO1HTR2ARETTSHRADRA2A
SCHEMBL44600 1.00 IDO1 (0.58) IDO1HTR2ARETTSHRADRA2A
Bromide SCHEMBL3727459 0.98 IDO1 (0.56) IDO1HTR2ARETADRA2AADRA1A
Methane SCHEMBL9503230 0.98 IDO1 (0.56) IDO1HTR2ARETADRA2AADRA1A
Hydrochloric Acid SCHEMBL7424398 0.98 IDO1 (0.59) IDO1HTR2ARET
Hydrochloric Acid SCHEMBL29757860 0.98 IDO1 (0.59) IDO1HTR2ARET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 829 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120152488-A Self-driven X-ray detector based on metal cation doped chiral perovskite and preparation method thereof 郑州大学 2025-06-13 CN claimed
CN-119899184-A Beta-carboline compound, preparation method thereof and application thereof in resisting Alzheimer disease 中国人民解放军北部战区总医院 2025-04-29 CN claimed
US-20250078176-A1 ENVIRONMENTAL ATTRIBUTES FOR NITROGEN CONTAINING CHEMICALS BASF SE (DE) 2025-03-06 US claimed
CN-119490460-A Preparation method of IDH1 mutant inhibitor 昆药集团股份有限公司 2025-02-21 CN claimed
US-12104106-B2 Compositions of chiral molecules and perovskite nanocrystals and methods of making the same ALLIANCE FOR SUSTAINABLE ENERGY, LLC (US) 2024-10-01 US claimed
CN-118684616-A Polymer composite material with circularly polarized room temperature phosphorescence characteristic and preparation method and application thereof 衡阳爱洁科技股份有限公司 2024-09-24 CN claimed
CN-118599796-A Lysine amine dehydrogenase mutant and application thereof in chiral amine compound synthesis 山东大学 2024-09-06 CN claimed
CN-116790686-A Method for synthesizing (R) -2- (1-aminoethyl) -4-fluorophenol by biological enzyme method 中国科学院青岛生物能源与过程研究所 2023-09-22 CN claimed
WO-2023117926-A1 ENVIRONMENTAL ATTRIBUTES FOR NITROGEN CONTAINING CHEMICALS BASF SE (DE) 2023-06-29 WO claimed
US-20220326082-A1 CHIRAL HETEROSTRUCTURES Alliance for Energy Innovation, LLC 2022-10-13 US claimed
WO-2013108227-A1 HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2013-07-25 WO claimed
CN-102675123-A Resolving and racemization method for 1-amino-1,2,3,4-tetrahydronaphthalene SHANGHAI LANGTZE BIOMEDICAL TECHNOLOGY CO LTD 2012-09-19 CN claimed
US-8084630-B2 Process for the synthesis of ramelteon and its intermediates TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2011-12-27 US claimed
EP-2098519-A1 Process for the synthesis of ramelteon and its intermediates Teva Pharmaceutical Industries Ltd. (IL) 2009-09-09 EP claimed
EP-1874748-B1 2 -AMINOCARBONYL SUBSTITUTED PIPERAZINE OR DIAZA-CYCLIC COMPOUNDS AS APOPTOSIS PROTEIN INHIBITOR (IAP) MODULATORS NOVARTIS AG (CH) 2009-08-12 EP claimed
EP-2069320-A2 PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES Teva Pharmaceutical Industries Ltd. (IL) 2009-06-17 EP claimed
US-20090069581-A1 PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2009-03-12 US claimed
WO-2008151170-A2 PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2008-12-11 WO claimed
WO-2008034032-A2 BETA-LACTAM CANNABINOID RECEPTOR MODULATORS AZEVAN PHARMACEUTICALS, INC. (US) 2008-03-20 WO claimed
WO-2007064272-A1 BENZHYDRYL AMIDE DERIVATIVES AS CANNABINOID RECEPTOR ANTAGONISTS OR INVERSE AGONISTS ASTRAZENECA AB (SE) 2007-06-07 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069581-A1 PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES CYP2B6, UGT1A6, CYP2A6 IDO1 2791/4885HTR2A 2028/4885RET 2809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.